Elevate your local knowledge
Sign up for the iNFOnews newsletter today!
MONTREAL – Valeant Pharmaceuticals International Inc. (NYSE: VRX) (TSX:VRX) has seen a sharp drop in third-quarter profits despite a healthy increase in revenue.
Canada’s largest publicly traded drug maker reported Friday that its net income for the three months ended Sept. 30 fell to just US$7.6 million or two cents per diluted share.
That compared with net earnings of US$40.9 million or 13 cents in the same 2011 period.
Revenue soared to US$884.1 million from US$570.4 million.
On a cash EPS basis, adjusted income was $357.5 million, or $1.15 per diluted share. Analysts expected Valeant’s adjust earnings to be US$1.12 per share based on 17 estimates compiled by Thomson Reuters.
Revenue was estimated at US$873.35 million, based on 15 estimates.
Valeant has made more than a dozen acquisitions this year to help strengthen its position as a global leader in dermatology products, including the recent purchase of U.S.-based Medicis Pharmaceutical Corp. for $2.6 billion.
Valeant also bought Dermik, a dermatological unit of Sanofi in the U.S. and Canada that manufactures, markets and sells a range of therapeutic and aesthetic dermatology products.
Last year, it bought Edmonton-based Afex Life Sciences, maker of the popular over-the-counter cold and flu remedy Cold-FX.
Another acquisition was iNova, which sells and distributes a range of prescription and over-the-counter products in Australia, New Zealand, Southeast Asia and South Africa.
Valeant, formed from the combination of California-based Valeant and the former Biovail pharmaceutical company, announced in April that it would move its global headquarters to Quebec to focus on over-the-counter dermatology products. It’s also setting up a research and development centre for consumer dermatology in Laval, north of Montreal.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Want to share your thoughts, add context, or connect with others in your community?
You must be logged in to post a comment.